Skip to main content

Cue Biopharma, Inc.

CUE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001645460

In the last 90 days, Cue Biopharma, Inc. insiders filed 0 open-market purchases and 3 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $52.2M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Cue Biopharma, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of CUE: Q1 2026 compared with Q2 2026
MeasureQ1 2026Q2 2026Change
Holders5750−7
Shares21.4M1.66M−19.8M (−92.3%)
Value$4.95M$52.2M+$47.3M (+954.7%)

New holders (14)

Institutions that held Cue Biopharma, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to CUE in Q2 2026
InstitutionSharesValue% of portfolio
Driehaus Capital Management LLC292,144$9.22M0.05%
Ikarian Capital, LLC104,364$3.29M0.54%
Polygon Management Ltd.93,819$2.96M0.48%
StemPoint Capital LP66,995$2.11M0.37%
ADAR1 Capital Management, LLC55,193$1.74M0.08%
Squadron Capital Management LLC50,000$1.58M0.54%
Boothbay Fund Management, LLC31,459$992.8K0.02%
Citadel Advisors LLC25,633$809.0K0.00%
Seven Fleet Capital Management LP10,702$337.8K0.06%
Tower Research Capital LLC (TRC)869$27.4K0.00%
SBI Securities Co., Ltd.300$9.47K0.00%
Group One Trading, L.P.30$9470.00%
Citigroup Inc1$320.00%
Caitong International Asset Management Co., Ltd1$320.00%

Sold out (21)

Institutions that held Cue Biopharma, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.